Shane Thomas Gleason Sells 7,073 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,073 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.51, for a total transaction of $17,753.23. Following the transaction, the insider directly owned 1,109,733 shares of the company’s stock, valued at $2,785,429.83. The trade was a 0.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Performance

NYSE:NSPR opened at $1.00 on Friday. The stock has a market capitalization of $46.84 million, a P/E ratio of -1.33 and a beta of 0.82. The company has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.66. InspireMD, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $2.93.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NSPR. Maxim Group began coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research report on Monday, May 4th. Finally, Loop Capital set a $5.00 price objective on shares of InspireMD in a research report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $4.50.

Institutional Investors Weigh In On InspireMD

A number of hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new stake in InspireMD during the 1st quarter worth approximately $29,000. Virtu Financial LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $31,000. XTX Topco Ltd acquired a new stake in InspireMD during the 4th quarter worth approximately $30,000. Orbimed Advisors LLC lifted its holdings in InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $203,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

More InspireMD News

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.